All In MedTech

FDA Clearance Tracker · P120023-S002

KAMRA INLAY

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 7, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 7, 2016

Approved

Time to decision

345 days

Received Oct 28, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P120023-S002
Device name
KAMRA INLAY
Applicant
Corneagen
Applicant location
Seattle, WA
Received
Oct 28, 2015
Decided
Oct 7, 2016
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P120023

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LQE

FDA's approval statement

As written in FDA's record.

Approval of incorporation of a new double tray packaging configuration in order to accommodate physicians' ease of use. The new packaging configuration has currently been validated for a 5-year shelf life. In addition, an alternate sterilization site, Sterigenics US LLC, has been validated for the proposed packaging.

Source documents

Other decisions for Corneagen

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.